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Berchieri [ 11 ingested vunil-positive Entemoccusfuecium 
strains isolated from animals in order to study the 
colonization of such strains in his intestinal gut. By this 
method, the author tried to provide crucial evidence of 
the link between the use of growth promoters in feed 
animals and the emergence of antibiotic resistance in 
humans. 
We [2] and others [3] have found identical clone 
pairs by pulsed-field gel electrophoresis (PFGE) of 
vancomycin-resistant enterococci (VRE) in fecal samples 
from humans and animals. This has been considered to 
be direct proof for animal-derived infection of VRE in 
humans. Moreover, the occurrence of VRE in feed 
animals has been linked with the use of the glyco- 
peptide avoparcin as a growth promoter in the EU until 
its ban in 1997. In my opinion, the presence of identical 
clone pairs cannot be regarded as direct proof, because 
it is not impossible- though very unlikely-that these 
clones came from a common source or that humans 
infected animals. Also, it was not shown whether these 
VRE in humans were colonizers or transient. Thus, a 
key experiment in humans is to ingest animal-derived 
vunA phenotypes of Enterococcitsfaecium and to observe 
the presence of these ingested organisms in fecal 
samples. Informed consent might be difficult to obtain, 
but Berchieri ingested two vunA phenotypes of Entero- 
coccusfnecium; one strain was derived from a chicken and 
another from a pig. He was able to show colonization 
with the chicken strain for approximately 3 weeks after 
ingestion of an inoculum of lo7 CFU. Five days after 
elimination of this strain, he ingested the pig strain. 
This strain was detected in stools for only 4 days after 
ingestion of an inoculum of lo7 CFU. When a high 
number of VRE were present in stools, he was also able 
to isolate VRE from perianal swabs. 
This is a very interesting and important observation 
which leads the author to conclude that ‘Vancoinycin- 
resistant E.  fuecium strains from pigs and poultry are 
able to colonize the human gut and the peri-anal skin’. 
However, I have several concerns about his inter- 
pretation of the results. 
First, the results of testing one strain isolated from 
a chicken and one from a pig in the same individual 
should not lead us to conclude that ‘strains from poultry 
and pig sources are able to colonize the gut of at least 
a proportion of the human population quite well’. 
More strains isolated from animals should be tested on 
a large number of volunteers. If, for ethical reasons, 
such a study is not possible, experiments with vanco- 
niycin-susceptible Enterococcus fuecium strains isolated 
from animals should be apppropriate for studying the 
colonization of animal-derived enterococci in the 
human gut. Second, although the method used for 
detection of VRE appears adequate, there is much 
concern about sensitivity (type of specimen, basic 
meha, indicator media, enrichment broths, vancomycin 
concentration) [4]. Third, the author provides no data 
on the identification methods used for enterococci. 
Fourth, and most important, the author provides no 
data on genotyping of the VRE or on the transposon 
type present in the animal- and human-derived strains. 
We can only assume that the author’s derived skm 
and stool isolates were identical, and that they were 
identical to the strains ingested. Indeed, mechanisms 
for cell-to-cell transfer of resistance elements carrying 
the vancomycin-resistance gene complex have been 
described for tmA, illustrating the high mobility of 
these resistance genes [5]. Thus, transfer of glyco- 
peptide resistance elements between Enterococcusfaecium 
strains may have occurred in the human gut. For 
instance, ‘human’ strains of Enterococcusfaecium colonizing 
the gut may have acquired the vancomycin resistance 
complex from the ingested animal strain. Van der 
Auwera et a1 [6] administered oral vancomycin and 
teicoplanin to healthy volunteers and found rapid 
emergence of VRE in some subjects. Moreover, they 
noticed great heterogeneity among the strains by 
PFGE, suggesting that genetic elements coding for 
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glycopeptide resistance may indeed have transferred 
between different enterococcal clones. Duval-Iflah et a1 
[7] have shown that plasniid transfer occurs between 
Estlztviciiia coli strains in the digestive tract but that the 
resulting transconjugants are generally not able to 
become established because the indigenous bacterial 
community exerts an antagonistic effect against strains 
which have acquired new genetic information. Thus, 
it would have been very interesting not only to 
compare the hunian- and animal-derived VRE by 
YFGE but also to study the transposon type. It is 
possible that transfer between Enterococccir fueciuvn strains 
may occur inore readily with certain transposon 
elements coding for vancomycin resistance than with 
others. Several transposon types have been found to be 
predominant in humans and animals. Aniong 160 
European animal and human isolates of vunA-positive 
enterococci, we found 9 different transposon types 
121. However, types 1 and 2 accounted together for 82% 
of the strains, and no host or enterococcal species 
specificity was observed. We also noticed the presence 
of different transposon types in VKE with the same 
PFGE results, which may indicate the high transfer- 
ability of the ti-ansposon. However, van den Braak et al 
[8] recently published data on the molecular charac- 
terization of VRE froin hospitalized patients and 
poultry products in The Netherlands. They noticed the 
emergence of two major PFGE types of VRE among 
poultry-derived strains which were not found in fecal 
floras of patients screened for VRE carriage in The 
Netherlands. They also concluded, based on mapping 
of the transposon, that there must be some sort of 
species barrier to the larger transposon type identified 
in their VRE, or limited conjugative transfer. More 
conflicting results concerning the host specificity of 
certain pulsed-field genotypes and transposon types 
have been published by others [9,10]. Careful selection 
of genotypes of VRE based on PFGE and of the 
transposon types based on transposon mapping for use 
in the experiments carried out by Berchieri may have 
provided evidence of the host specificity of VRE and 
of the transfer of vancomycin resistance elenients in 
vivo between enterococci. It  has been shown that 
different serogroups and biotypes of some important 
streptococci are host-associated ecovars 11 I]. Although 
there is less evidence than for streptococci, the question 
remains BS to whether enterococci behave like strepto- 
cocci. 
The use of antibiotics as growth promoters in feed 
animals has been a matter of debate for more than 
30 years. However, in my opinion, discussions should 
occur at two levels. 
The first level of (strictly scientific) discussion 
should deal with the evidence that the use of growth 
promoters in feed animals is responsible for the 
emergence of antibiotic resistance in humans. The 
emergence of such resistance in humans after ingestion 
of animal-derived strains via the food chain can occur 
in three ways: infection with resistant organisms in the 
gut without colonization; colonization in the gut; or 
clinical infection. This distinction is important because 
it causes confusion during discussions on the adverse 
effects of growth promoters. The second level should 
deal with the broader question of the use of chemo- 
therapeutic antibiotics for growth stimulation of food 
animals. This has become a very complicated subject 
because it involves not only the scientific evidence for 
a link, but also other items, such as animal hygiene, best 
management practices, the use of alternatives such as 
probiotics and vaccination, economic and environ- 
mental consequences of a ban on growth promoters, 
and world trade. Currently, recommendations and 
decisions concerning the banning of growth promoters 
are based only on the scientific evidence provided. The 
use of avoparcin was banned in Sweden in 1986, in 
Denmark in 2995, in Germany 111 1996 and in the rest 
of the EU in April 1997. Virginiamycin was banned 
in January 1998 in Denmark. In December 1998, the 
EU Commission suspended avilamycin, bacitracin, 
tylosin and virginianiycin. Avilamycin, an oligosac- 
charide, is structurally very similar to everninoniicins 
1121. The compound everninoniicin SCH 27899 is 
very active against niultiresistant Gram-positive bacteria 
[ 3 31. Recently, Aarestrup found complete agreement 
between decreased susceptibility to avilamycin and 
everninomicin SCH 27899 for Etiferococcus.fierium and 
Enterocoms  jieculis isolated from broilers and pigs [14]. 
Is this enough evidence to justify the banning of 
avilaniycin as the third antibacterial growth promoter 
in Denmark? Thus, with more and more data being 
published on avilamycin, avoparcin, bacitracin, tylosin 
and virginiamycin, at what point do we consider the 
evidence scientifically sound enough to justify a ban 
on all or some of these growth promoters? Do we 
recommend a ban when animal-derived resistant strains 
are able to colonize the human intestinal gut and/or 
when they are able to transfer resistance elements 
and/or when they are causing clinical infection in 
humans? In my opinion, the issue of intestinal colon- 
ization and transfer in vivo of resistance elements is 
crucial in the debate on the impact of growth promoters 
on the emergence of resistance in humans. This is why 
I welcome the study by Berchieri. 
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